🇧🇪 ARGX.BR — argenx SE

Salud Compra fuerte
← Volver

Precio actual

815,80 EUR

Máx. histórico

912,40

64 días

Caída desde máximo

-10,59%

Rango 52 semanas

568,40 – 925,00

Variación hoy

+0,03%

Cierre anterior

815,60

Rango de hoy

788,80 – 815,80

Volumen hoy

102.849

Peor caída histórica

-39,26%

21/07/2023 → 21/12/2023

Recuperado en 262 días

Volatilidad anualizada ⓘ

43,77%

Información
Nombre completo
argenx SE
Divisa
EUR
Mercado
Brussels
Sector
Salud
Industria
Biotechnology
Empleados
1.863
PER ⓘ
32,83 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
1.005,32 EUR (puede no estar actualizado)
Primera cotización
10/07/2014
Precio actualizado
hace 1 día
Sobre la empresa

argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction; ARGX-124, a FcRn pipeline candidate; ARGX-109, which targets IL-6 to treat inflammation; ARGX-121, which targets immunoglobulin A; and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases; OncoVerity, Inc for cusatuzumab; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
16/11/2018 81,30 82,80 80,40 82,30 +0,86% 2,95% 129.689
15/11/2018 82,40 83,30 80,60 81,60 -1,69% 3,28% 108.369
14/11/2018 83,20 87,00 82,20 83,00 -1,78% 5,77% 158.907
13/11/2018 83,00 85,10 82,60 84,50 +2,55% 3,01% 72.439
12/11/2018 85,70 86,40 82,20 82,40 -3,85% 4,90% 77.570
09/11/2018 85,50 87,40 84,80 85,70 -1,49% 3,04% 61.238
08/11/2018 87,00 87,70 84,90 87,00 +0,23% 3,22% 50.694
07/11/2018 87,30 90,00 86,50 86,80 +0,12% 4,01% 142.149
06/11/2018 85,00 86,90 84,20 86,70 +4,46% 3,18% 104.870
05/11/2018 84,00 84,30 82,10 83,00 -1,07% 2,62% 78.664
02/11/2018 83,00 84,90 82,00 83,90 +5,27% 3,49% 178.518
01/11/2018 70,60 82,20 70,40 79,70 +13,69% 16,71% 244.737
31/10/2018 67,00 70,50 66,00 70,10 +6,37% 6,72% 82.695
30/10/2018 66,30 66,90 64,20 65,90 -0,60% 4,07% 58.103
29/10/2018 64,00 67,40 63,70 66,30 +3,27% 5,78% 42.793
26/10/2018 65,50 65,90 63,00 64,20 -1,98% 4,43% 98.633
25/10/2018 67,50 69,30 65,10 65,50 -6,16% 6,22% 124.706
24/10/2018 71,50 72,10 69,80 69,80 +0,00% 3,22% 50.272
23/10/2018 71,00 71,60 69,40 69,80 -2,51% 3,10% 147.065
22/10/2018 72,00 72,20 70,20 71,60 -2,32% 2,78% 70.912
19/10/2018 73,10 73,50 71,10 73,30 -0,27% 3,28% 78.725
18/10/2018 67,70 74,60 67,50 73,50 +10,03% 10,49% 207.695
17/10/2018 66,80 68,60 66,30 66,80 +1,06% 3,44% 70.660
16/10/2018 63,90 66,60 63,70 66,10 +4,59% 4,54% 62.857
15/10/2018 63,20 65,20 62,00 63,20 +0,32% 5,06% 113.273
12/10/2018 63,70 64,90 62,50 63,00 +5,70% 3,77% 168.543
11/10/2018 55,50 62,90 54,30 59,60 +3,65% 15,50% 314.087
10/10/2018 60,90 61,10 57,40 57,50 -5,58% 6,08% 149.606
09/10/2018 61,60 63,50 60,60 60,90 -0,33% 4,71% 153.390
08/10/2018 64,00 64,10 60,90 61,10 -4,83% 5,00% 129.660